| Market Capitalization (Millions $) |
140 |
| Shares
Outstanding (Millions) |
67 |
| Employees |
65 |
| Revenues (TTM) (Millions $) |
0 |
| Net Income (TTM) (Millions $) |
-67 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
InflaRx N.V. is a clinical-stage biopharmaceutical company that focuses on discovering and developing first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and small molecule inhibitors of C5aR. They aim to address a wide range of complement-mediated diseases with significant unmet medical needs, including severe COVID-19, pyoderma gangrenosum, hidradenitis suppurativa, and ANCA-associated vasculitis. InflaRx's lead product candidate is vilobelimab, a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings. They are also developing IFX002, a life-cycle management product for vilobelimab, and INF904, an orally administered, small-molecule inhibitor of C5aR. InflaRx was founded in 2007 as InflaRx GmbH by Professor Niels Riedemann and Professor Renfeng Guo in Jena, Germany. The company employs a total of 48 employees, 18 of whom have M.D. or Ph.D. degrees. The company's management team has extensive experience in the field of complement research, clinical research, and the biopharmaceutical industry.
Company Address: Winzerlaer Str. 2 Jena 0
Company Phone Number: (3641) 508 180 Stock Exchange / Ticker: NASDAQ IFRX
|
